These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28428276)

  • 1. Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer.
    Wen D; Peng Y; Lin F; Singh RK; Mahato RI
    Cancer Res; 2017 Jun; 77(12):3244-3254. PubMed ID: 28428276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer.
    Lin F; Wen D; Wang X; Mahato RI
    Biomaterials; 2019 Feb; 192():95-108. PubMed ID: 30447399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
    Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
    Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
    Kojima K; Fujita Y; Nozawa Y; Deguchi T; Ito M
    Prostate; 2010 Oct; 70(14):1501-12. PubMed ID: 20687223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
    Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
    Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.
    Li X; Han X; Wei P; Yang J; Sun J
    Cancer Biol Ther; 2020 May; 21(5):452-462. PubMed ID: 32089062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboxymethyl Dextran-Stabilized Polyethylenimine-Poly(epsilon-caprolactone) Nanoparticles-Mediated Modulation of MicroRNA-34a Expression via Small-Molecule Modulator for Hepatocellular Carcinoma Therapy.
    Deng X; Yin Z; Zhou Z; Wang Y; Zhang F; Hu Q; Yang Y; Lu J; Wu Y; Sheng W; Zeng Y
    ACS Appl Mater Interfaces; 2016 Jul; 8(27):17068-79. PubMed ID: 27300477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymeric Micellar Delivery of Novel Microtubule Destabilizer and Hedgehog Signaling Inhibitor for Treating Chemoresistant Prostate Cancer.
    Yang R; Chen H; Guo D; Dong Y; Miller DD; Li W; Mahato RI
    J Pharmacol Exp Ther; 2019 Sep; 370(3):864-875. PubMed ID: 30996033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy.
    Yao C; Liu J; Wu X; Tai Z; Gao Y; Zhu Q; Li J; Zhang L; Hu C; Gu F; Gao J; Gao S
    J Control Release; 2016 Jun; 232():203-14. PubMed ID: 27126903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells.
    Fujita Y; Kojima K; Hamada N; Ohhashi R; Akao Y; Nozawa Y; Deguchi T; Ito M
    Biochem Biophys Res Commun; 2008 Dec; 377(1):114-9. PubMed ID: 18834855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.
    Singh S; Chitkara D; Mehrazin R; Behrman SW; Wake RW; Mahato RI
    PLoS One; 2012; 7(6):e40021. PubMed ID: 22768203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma.
    Xiao Z; Li CH; Chan SL; Xu F; Feng L; Wang Y; Jiang JD; Sung JJ; Cheng CH; Chen Y
    Cancer Res; 2014 Nov; 74(21):6236-47. PubMed ID: 25217526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer.
    Li F; Danquah M; Singh S; Wu H; Mahato RI
    Drug Deliv Transl Res; 2011 Dec; 1(6):420-8. PubMed ID: 25786362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
    Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells.
    Zhu M; Zheng Z; Huang J; Ma X; Huang C; Wu R; Li X; Liang Z; Deng F; Wu J; Geng S; Xie C; Zhong C
    J Cell Biochem; 2019 Sep; 120(9):15616-15624. PubMed ID: 31042325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy.
    Gaur S; Wen Y; Song JH; Parikh NU; Mangala LS; Blessing AM; Ivan C; Wu SY; Varkaris A; Shi Y; Lopez-Berestein G; Frigo DE; Sood AK; Gallick GE
    Oncotarget; 2015 Oct; 6(30):29161-77. PubMed ID: 26313360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis.
    Li B; Jin X; Meng H; Hu B; Zhang T; Yu J; Chen S; Guo X; Wang W; Jiang W; Wang J
    Oncotarget; 2017 Jul; 8(29):47849-47860. PubMed ID: 28599307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1.
    Chen L; Cao H; Feng Y
    World J Urol; 2018 Mar; 36(3):357-365. PubMed ID: 29204706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
    Pu Y; Zhao F; Li Y; Cui M; Wang H; Meng X; Cai S
    BMC Cancer; 2017 Jan; 17(1):45. PubMed ID: 28073349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skp2 is associated with paclitaxel resistance in prostate cancer cells.
    Yang Y; Lu Y; Wang L; Mizokami A; Keller ET; Zhang J; Fu J
    Oncol Rep; 2016 Jul; 36(1):559-66. PubMed ID: 27175797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.